Arthur He
Stock Analyst at HC Wainwright & Co.
(4.11)
# 548
Out of 5,008 analysts
62
Total ratings
49.18%
Success rate
16.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADAG Adagene | Maintains: Buy | $8 → $7 | $1.99 | +251.76% | 11 | Aug 15, 2025 | |
| LVTX LAVA Therapeutics | Maintains: Neutral | $1.5 → $1.24 | $1.61 | -22.74% | 11 | Aug 5, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $11.71 | +45.18% | 1 | Jul 30, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | n/a | $0.14 | - | 7 | Jul 29, 2025 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $6.5 → $120 | $58.00 | +106.90% | 4 | Jun 24, 2025 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $5.52 | +262.32% | 10 | Jun 17, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $75 → $85 | $30.80 | +175.97% | 2 | Jun 2, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $5.87 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $0.80 | - | 8 | Mar 31, 2025 |
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.99
Upside: +251.76%
LAVA Therapeutics
Aug 5, 2025
Maintains: Neutral
Price Target: $1.5 → $1.24
Current: $1.61
Upside: -22.74%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $11.71
Upside: +45.18%
Adaptimmune Therapeutics
Jul 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.14
Upside: -
Nektar Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $6.5 → $120
Current: $58.00
Upside: +106.90%
Solid Biosciences
Jun 17, 2025
Reiterates: Buy
Price Target: $20
Current: $5.52
Upside: +262.32%
Vera Therapeutics
Jun 2, 2025
Maintains: Buy
Price Target: $75 → $85
Current: $30.80
Upside: +175.97%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $5.87
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $0.80
Upside: -